What are the recommended adult and pediatric dosing schedules for the commonly used therapeutic monoclonal antibodies?

Monoclonal Antibody Dosing: Adult and Pediatric Recommendations

For most therapeutic monoclonal antibodies, adult dosing is typically fixed (e.g., 200-400 mg) or weight-based (e.g., 5 mg/kg), while pediatric dosing generally follows weight-based calculations with a threshold of 40 kg body weight above which adult fixed doses can be used.

Adult Dosing Regimens

Based on FDA-approved biologics for psoriasis and other indications, the following represent standard adult dosing schedules 1:

TNF-α Inhibitors

• Etanercept: 50 mg subcutaneous weekly (maintenance)
• Adalimumab: 80 mg initial dose (2 × 40 mg), then 40 mg subcutaneous every 2 weeks
• Infliximab: 5 mg/kg IV at weeks 0,2,6, then every 8 weeks
• Certolizumab: 400 mg every other week (or 200 mg every other week for patients <90 kg)

IL-12/IL-23 Inhibitors

• Ustekinumab:
  • ≤100 kg: 45 mg subcutaneous at weeks 0,4, then every 12 weeks

  • 100 kg: 90 mg subcutaneous at weeks 0,4, then every 12 weeks 1

IL-17 Inhibitors

• Secukinumab: 300 mg subcutaneous at weeks 0,1,2,3,4, then every 4 weeks
• Ixekizumab: 160 mg initial, then 80 mg at weeks 2,4,6,8,10,12, then every 4 weeks
• Brodalumab: 210 mg subcutaneous at weeks 0,1,2, then every 2 weeks

IL-23 Inhibitors

• Guselkumab: 100 mg subcutaneous at weeks 0,4, then every 8 weeks
• Tildrakizumab: 100 mg subcutaneous at weeks 0,4, then every 12 weeks 1

Pediatric Dosing Strategies

Weight-Based Dosing for Children

The critical principle: pediatric dosing for monoclonal antibodies primarily depends on body weight, with allometric scaling being the most reliable approach 2, 3.

For children aged 4-17 years with psoriasis 2:

• Etanercept: 0.8 mg/kg weekly subcutaneous (maximum 50 mg if ≤63 kg)
• Adalimumab: 24 mg/m² or 0.8 mg/kg (maximum 40 mg) weekly for first 2 weeks, then every 2 weeks
• Infliximab: 5 mg/kg IV at weeks 0,2,6, then every 8 weeks
• Ustekinumab (ages 12-17):
  • <60 kg: 0.75 mg/kg
  • 60-100 kg: 45 mg

  • 100 kg: 90 mg

  • Administered at weeks 0,4, then every 12 weeks 1

Weight Threshold for Adult Dosing

Research demonstrates that pediatric patients ≥40 kg body weight can generally receive adult fixed doses for monoclonal antibodies with linear pharmacokinetics 4. This threshold ensures pediatric exposures remain within 20-30% of adult median exposures when the reference adult population has median weight ≤80 kg.

Key considerations for the 40 kg threshold 4:

• Applies to mAbs with wide therapeutic windows
• Assumes linear elimination kinetics
• Requires consideration of the drug's therapeutic index
• May need adjustment if adult reference population is heavier

Age-Specific Considerations

For children 6-17 years: Pharmacokinetics are highly predictable using allometric scaling from adult data, with weight exponents of 0.75 for clearance and 1.0 for volume of distribution 5.

For children 2-5 years: Limited data exists, but the Salisbury Rule (a weight-based prediction method) shows 87-92% accuracy within acceptable prediction error for children <30 kg 6.

For neonates and infants: Age-associated differences beyond body size become more significant, requiring specific pharmacokinetic studies rather than simple extrapolation 3.

Practical Dosing Algorithm

1. Determine patient weight

   • ≥40 kg → Consider adult fixed dose
   • <40 kg → Use weight-based pediatric dosing

2. For weight-based dosing

   • Calculate dose using mg/kg or mg/m² as specified
   • Apply maximum dose caps where indicated
   • Round to practical vial sizes

3. Verify age appropriateness

   • Etanercept: FDA-approved ≥4 years
   • Ustekinumab: FDA-approved ≥12 years 1
   • Other biologics: typically off-label in pediatrics

Important Caveats

• Immunogenicity: Pediatric patients may have different immunogenic responses than adults, potentially affecting long-term efficacy 3
• Loading doses: Most regimens require higher initial dosing or more frequent administration during induction phase
• Dose escalation: Can increase frequency (e.g., ustekinumab every 8 weeks instead of 12 weeks) or dose (e.g., 90 mg instead of 45 mg) for inadequate response 1
• Non-linear kinetics: The 40 kg threshold applies primarily to mAbs with linear pharmacokinetics; target-mediated drug disposition may require different approaches 4